

The 26th Annual Joseph Chin Fall Review in Urologic Oncology

October 14 – 16, 2022

Oakwood Inn, Grand Bend, Ontario

Agenda

By the end of this program, participants will be able to:

1. Identify recent developments and state of the art management concepts in prostate cancer, bladder and renal cancer. CanMeds roles fulfilled: Communication (with community colleagues), Collaboration (with community colleagues), Advocacy (for patients to achieve the best care)

2. Review new concepts and techniques in radiation therapy. CanMeds roles fulfilled: Medical expert (with knowledge transfer), Scholar (with academic discussion on latest evidence from basic, translational and clinical research).

3. Discuss complex uro-oncologic cases using rationale and relevant clinical evidence. CanMeds roles fulfilled: Communication (with community colleagues), Collaboration (with community colleagues), Advocacy (for patients to achieve the best care).

4. Identify available clinical trials for difficult/challenging case. CanMeds roles fulfilled: Medical expert, Scholar (engaging in clinical trials), Leader (with novel therapies). Advocacy (for optimal patient care opportunities).

Friday October 14th, 2022

6: 00 – 9:00 pm *Arrivals / Speaker Support*

Saturday October 15th, 2022

7:00 – 8:00 am	Breakfast	Oak Dining Room
8:00 - 8:05	Welcoming Remarks & Introduction Drs. Joe Chin & Nick Power	Huron Room
8:05- 8:25	“History of the UWO Fall Review” Dr. Joe Chin	

October 15, 2022

8:25 – 8:55

“Renal Cryoablation: Why is Cool so Hot”

Dr. Brad Halkier

Objectives: By the end of this session, participants will be able to:

1. Describe the indications for minimally invasive procedures for small renal masses
2. Identify and comprehend therapeutic options for small renal masses
3. Summarize the results of cryoablation at a high volume centre and apply to participants’ own patients

8:55 - 9:25

“Percutaneous Renal Ablation: Local Trends, Outcomes and Future Direction”

Dr. Derek Cool

Objectives: By the end of this session, participants will be able to:

1. Recognize the ablative options in the SW Ont. region
2. Discuss the local therapeutic algorithm and patient selection for minimally invasive treatment for small renal masses
3. Discuss the local experience in ablative therapies for small renal masses and to apply to future management cases

9:25 – 9:55

“Neoadjuvant therapy in the genomics era”

Dr. Colin Dinney

Objectives: by the end of this session the participants will be able to:

1. Summarize state-of-the-art therapeutic options for urothelial cancer
2. Apply new insights in genomics in therapeutic guidance for urothelial cancer
3. Describe the experience of neoadjuvant therapy at MD Anderson Cancer Centre (MDACC)

9:55 - 10:20

Health Break

10:20 - 10:50

“Therapy for High-Risk Non-Muscle Invasive Bladder Cancer”

Dr. Colin Dinney

Objectives: by the end of this session the participants will be able to:

1. Describe the landscape of management options for high risk non-muscle invasive bladder cancer
2. Summarize the therapeutic options and the pros and cons of each option to one’s own practice
3. Recognize the management at MDACC of high-risk non-muscle invasive urothelial cancer and to analyze the relevance for the local treatment set-up

10:50– 11:20

Introduction by Dr Glenn Bauman

“Improving Patient Outcomes with PSMA PET-guided Therapy”

Dr. Cynthia Menard

Objectives: by the end of this session the participants will be able to:

1. Discuss the updated results on PET imaging for prostate cancer
2. Describe the landscape of PSMA PET guided therapy in Canada and globally
3. Apply patient selection for trials involving PSMA PET-guided therapy

11:20 - 11:50

“MRI-guided Focal Brachytherapy for Prostate Cancer”

Dr. Cynthia Menard

Objectives: by the end of this sessions the participants will be able to:

1. Define updated on the concept of focal therapy for prostate cancer
2. Discuss the landscape of MRI-guided brachytherapy in Canada and globally
3. Apply patient selection and data from MRI-guided focal brachytherapy to one’s own practice

October 15, 2022

- 11:50 – 1:00 pm Multi-disciplinary Case Conference – part one
Drs. Karim Marzouk, Melissa Huynh, C. Dinney, C. Menard, Eric Winquist
Objectives: by the end of this session the participants will be able to:
1. *Assess difficult cases of prostate, bladder and kidney and penile cancer*
 2. *Review management options on the difficult oncology cases*
 3. *Apply novel management and clinical trials opportunities to participants' own cases*
- 1:00 – 2:00 pm *Lunch Break* Oak Dining Room
- 2:00 - 2:30 “Framing Effect on Outcomes of Clinical Trials” Huron Room
Dr. Nick Power
Objectives: by the end of this session, participants will be able to:
1. *Describe updated on the rationale and the mechanics of clinical trials*
 2. *Review clinical trials outcomes and downstream consequences*
 3. *Analyze factors which might affect the outcome of clinical trials and to apply to one's own patients*
- 2:30 - 3:00 “Beyond the diagnosis: Mental health and wellness for patients with prostate cancer”
Dr. Jeff Campbell
Objectives: by the end of this session, participants will be able to:
1. *Describe the concepts mental health and wellness with the diagnosis of malignancy, and specifically prostate cancer*
 2. *Review holistic concepts in management of prostate cancer*
 3. *Apply these concepts into the management routine of prostate cancer*
- 3:00 - 3:30 “Is there a Role for Docetaxel in Castration-sensitive Metastatic Prostate Cancer?”
Dr. Eric Winquist
Objectives: by the end of this session, participants will be able to:
1. *Discuss the landscape of castration-sensitive metastatic prostate cancer management*
 2. *Analyze data from recent clinical trials on Docetaxel for prostate cancer*
 3. *Recognize pros and cons of early use of docetaxel in castration-sensitive metastatic prostate cancer and to apply to one's own patients*
- 3:30 - 4:00 “Hereditary Kidney Cancer Syndromes: What's New for the Urologist”
Dr. Steve Pautler
Objectives: by the end of this session participants will be able to:
1. *Describe more on updated hereditary kidney cancer diagnoses*
 2. *Analyze and apply current management of hereditary kidney cancer syndromes*
 3. *Apply new concepts and drugs for hereditary kidney cancer syndromes*
- 4:00 – 4:15 Discussion/ Concluding Remarks / Look ahead to next day
Dr. Nick Power

Dinner will be served from 7:30 pm in the Oak Dining Room

Sunday, October 16th, 2022

7:30 – 8:30 am	Breakfast	Oak Dining Room
8:30 - 8:35	Welcoming Remarks & Introduction Drs. Joe Chin & Nick Power	Huron Room
8:30 - 9:05	“Role of the Gut Microbiome in Renal Cell Carcinoma” Dr. Ricardo Fernandes Objectives: by the end of this session, participants will be able to: <ol style="list-style-type: none">1. Summarize new concepts of gut microbiome2. Describe the relationship of gut microbiome and systemic therapies3. Analyze and apply the data on the role of gut microbiome on renal cell carcinoma therapy	
9:05 – 9:35	Clinical Trials Update Dr. Joseph Chin, Dr. Eric Winquist, Dr. Glenn Bauman Objectives: by the end of this session the participants will be able to: <ol style="list-style-type: none">1. Describe about clinical trials currently accruing in the SW Ont. region2. Analyze eligibility and opportunities for the difficult cases for clinical trials3. Apply referral patterns for the difficult cases and to execute collaborative efforts	
9:35 – 9:50	Health Break	
9:50 – 11:20	Multi-disciplinary Case Conference – part two Drs K. Marzouk, M. Huynh, N. Power, E. Winquist Objectives: by the end of this session the participants will be able to: <ol style="list-style-type: none">1. Describe difficult cases of prostate, bladder and kidney and penile cancer2. Assess management options on the difficult oncology cases3. Apply novel management and clinical trials opportunities to participants’ own cases	
11:20 – 11:30	Closing remarks / evaluation / adjourn	

*Note: 25% of this program is dedicated to participant interaction

*This program has received educational grants from:
Abbvie, Astellas, Bayer, Boston Scientific, Janssen,
Knight, Merck, Pfizer, TerSera, Tolmar*